Director/PDMR Shareholding
02 Maggio 2024 - 8:00AM
UK Regulatory
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the
“Company”), the AQSE Growth Market quoted clinical decision support
developer and supplier of clinical decision support systems has
received notification that on 30 April 2024 Mr Bob Sutcliffe, tha
Chairman, purchased a total of 100,000 Ordinary Shares in the
Company at a price of 1.46p per share.
Following this transaction Mr Sutcliffe and his
wife’s interest in DXS Ordinary Shares is 933,386 Ordinary Shares
representing 1.46% of the issued share capital of the Company.
1
|
Details of the person discharging managerial
responsibilities / person closely associated |
a)
|
Name
|
Robert Sutcliffe
|
|
2 |
Reason for the notification |
a)
|
Position/status
|
Chairman |
b)
|
Initial notification /Amendment
|
Initial |
3
|
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
|
a)
|
Name
|
DXS INTERNATIONAL PLC |
b)
|
LEI
|
2138001R1KEUWTXEVJ44 |
4
|
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.33p each |
|
|
|
|
Identification code |
ISIN GB00B2Q6HZ92 |
|
|
|
b)
|
Nature of the transaction
|
Issue of new shares |
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
1.46p |
100,000 |
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
e)
|
Date of the transaction
|
30 April 2024 |
f)
|
Place of the transaction
|
Aquis Stock Exchange |
The Directors of DXS International plc accept
responsibility for this announcement.
Enquiries:
David
Immelman (Chief Executive)
DXS International plc |
01252 719800
david@dxs-systems.com |
Wrecclesham
House
Wrecclesham Road
Farnham
Surrey
GU10 4PS |
|
|
www.dxs-systems.co.uk |
|
Corporate
Advisor
|
|
David
Papworth
City & Merchant |
0207 101 7676
|
Corporate
Broker
|
|
Hybridan
LLP
Claire Louise Noyce
|
020 3764 2341
|
Note to Editors:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
Grafico Azioni DXS (AQSE:DXSP)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni DXS (AQSE:DXSP)
Storico
Da Nov 2023 a Nov 2024
